List of Sapio LIMS Customers
Baltimore, 21202, MD,
United States
Since 2010, our global team of researchers has been studying Sapio LIMS customers around the world, aggregating massive amounts of data points that form the basis of our forecast assumptions and perhaps the rise and fall of certain vendors and their products on a quarterly basis.
Each quarter our research team identifies companies that have purchased Sapio LIMS for Laboratory Management from public (Press Releases, Customer References, Testimonials, Case Studies and Success Stories) and proprietary sources, including the customer size, industry, location, implementation status, partner involvement, LOB Key Stakeholders and related IT decision-makers contact details.
Companies using Sapio LIMS for Laboratory Management include: Regeneron Pharmaceuticals, a United States based Life Sciences organisation with 15182 employees and revenues of $142.02 billion, AstraZeneca, a United Kingdom based Life Sciences organisation with 94300 employees and revenues of $73.98 billion, Bristol Myers Squibb, a United States based Life Sciences organisation with 34100 employees and revenues of $48.30 billion, University of California San Francisco, a United States based Education organisation with 5063 employees and revenues of $9.45 billion, Oslo University Hospital, a Norway based Healthcare organisation with 24000 employees and revenues of $2.77 billion and many others.
Contact us if you need a completed and verified list of companies using Sapio LIMS, including the breakdown by industry (21 Verticals), Geography (Region, Country, State, City), Company Size (Revenue, Employees, Asset) and related IT Decision Makers, Key Stakeholders, business and technology executives responsible for the software purchases.
The Sapio LIMS customer wins are being incorporated in our Enterprise Applications Buyer Insight and Technographics Customer Database which has over 100 data fields that detail company usage of software systems and their digital transformation initiatives. Apps Run The World wants to become your No. 1 technographic data source!
Apply Filters For Customers
| Logo | Customer | Industry | Empl. | Revenue | Country | Vendor | Application | Category | When | SI | Insight |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
2Seventy bio | Life Sciences | 437 | $51M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2023 | n/a |
In 2023, 2Seventy bio implemented Sapio LIMS as its Laboratory Management application to centralize R&D sample and inventory workflows. The rollout focused on the Cambridge M.A. research site and encompassed R&D labs and the Flow Cytometry Core, covering tasks including gDNA extraction for VCN processes, T cell production expansions, and organization of cell culture workflows for all R&D cell lines.
Sapio LIMS was configured with front end development improvements and data storage process updates to support reagent production and inventory management workflows. Functional capabilities implemented included sample tracking and chain of custody for tumor and transduced cell lines, reagent lot and production records for R&D reagents used in tumor cell line production and T cell de-risking assays, and assay workflow orchestration for panel implementation in flow cytometry.
Instrument and data automation integrations were applied where supported by laboratory practice, notably the incorporation of a python script for flow cytometry automation to handle auditing, data collection, and raw data transference into Sapio LIMS. The implementation also embedded operational controls for maintenance and qualification of flow cytometers, and supported vendor coordination with providers for Flow Cytometry, MSD, and cell line viability supplies to ensure experiment longevity and operational quality.
Governance and operational ownership were aligned to scientific functions, with the Flow Cytometry Core Lead and Technical Associate Research and Technology roles overseeing instrument maintenance, new antibody staining reagent assays, and oncology shipping and storage through Sapio LIMS. Process changes emphasized formalized inventory and shipping records, reagent production documentation, and data auditing workflows within the Laboratory Management application Sapio LIMS.
|
 |
4D Molecular Therapeutics | Life Sciences | 147 | $20M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2022 | n/a |
In 2022, 4D Molecular Therapeutics implemented Sapio LIMS to support Supply Chain functions. The Sapio LIMS deployment targeted Laboratory Management workflows and was positioned to instrument clinical supply and CMC interfaces across the organization.
The Sapio LIMS implementation was configured to address core Laboratory Management capabilities, including inventory management, sample and kit tracking, pack and label workflows, and depot activity orchestration. Configuration emphasized chain of custody records and audit-ready documentation to support clinical program material handling and traceability.
Operational scope covered Supply Chain and CMC support for five clinical programs, with direct oversight of depot activities to ensure pack and label tasks met program needs. The deployment was planned and executed with supply chain ownership for Trial Master File filing needs and included forward-looking improvement planning for broader process adoption.
Governance and process workstreams included establishing TMF filing ownership on behalf of CMC, conducting a gap assessment between early clinical practices and later phase EU compliance, and planning actionable items to bridge those gaps with minimal supervision. Sapio LIMS serves as the Laboratory Management application centralizing supply chain workflows, pack and label operations, and clinical material governance across affected business functions.
|
 |
Arcturus Therapeutics | Life Sciences | 177 | $12M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2022 | n/a |
In 2022 Arcturus Therapeutics implemented Sapio LIMS for its bioanalytical operations within the Laboratory Management category. The program was driven by the in-house bioanalytical team and included feasibility assessment, iterative feature development, workflow customization, and structured data validation to support regulated research activities.
Sapio LIMS was configured with custom mechanisms to mirror bioanalytical workflows, emphasizing electronic sample tracking, chain of custody, and enhanced traceability across mRNA, lipid, and protein assays. Configuration work included mapping study metadata, creating controlled data capture templates, and embedding validation checkpoints to enforce structured data standards used during regulatory readiness reviews.
Operational coverage focused on the bioanalytical group and upstream early-stage R&D stakeholders, supporting large-scale data operations for mRNA, lipid, and protein quantification. Data normalization and analysis workflows were supplemented by Excel based processes, including PivotTables to normalize and analyze thousands of data points, maintaining alignment with the LIMS data model and audit documentation practices.
Governance and sustainment were formalized through a biweekly partnership between the Research Associate II and the system administrator to troubleshoot issues and deliver continuous improvements. Documentation practices included authoring technical reports for method qualifications, sample analysis, and study summaries to support auditability, and laboratory workstreams included development of three singleplex protein quantification assays on the MSD platform which enabled higher throughput and reduced per-sample cost by 20x.
|
 |
|
Life Sciences | 85 | $9M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2022 | n/a |
|
|
|
|
Life Sciences | 94300 | $74.0B | United Kingdom | Sapio Sciences | Sapio LIMS | Laboratory Management | 2025 | n/a |
|
|
|
|
Life Sciences | 190 | $40M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2023 | n/a |
|
|
|
|
Life Sciences | 273 | $71M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2022 | n/a |
|
|
|
|
Healthcare | 3300 | $400M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2022 | n/a |
|
|
|
|
Life Sciences | 248 | $84M | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2020 | n/a |
|
|
|
|
Life Sciences | 34100 | $48.3B | United States | Sapio Sciences | Sapio LIMS | Laboratory Management | 2018 | n/a |
|
Buyer Intent: Companies Evaluating Sapio LIMS
Discover Software Buyers actively Evaluating Enterprise Applications
| Logo | Company | Industry | Employees | Revenue | Country | Evaluated | ||
|---|---|---|---|---|---|---|---|---|
| No data found | ||||||||